Le Lézard
Classified in: Health, Business
Subject: TNM

Acquisition of Units of SQI Diagnostics Inc.


/NOT FOR DISSEMINATION IN THE UNITED STATES OR OVER UNITED STATES NEWSWIRE SERVICES/

TORONTO, March 5, 2020 /CNW/ - Mr. Wilmot L. Matthews ("Mr. Matthews") announces that he has acquired 14,814,814 common shares and 14,814,814 common share purchase warrants of SQI Diagnostics Inc. ("SQI"), representing an increase of approximately 4.22% of the issued and outstanding common shares of SQI on a non-diluted basis and an increase of approximately 5.81% of the issued and outstanding common shares of SQI, assuming the exercise of all common share purchase warrants of SQI that Mr. Matthews beneficially owns or exercises control or direction over. The securities were acquired by Mr. Matthews in connection with a private placement offering of units of SQI ("Units") at a price of $0.09 per Unit for aggregate consideration of $1,333,333. Mr. Matthews has been a director of SQI since April 8, 2015.

Immediately prior to the acquisition, Mr. Matthews beneficially owned or exercised control or direction over 55,456,351 common shares, 48,209,248 common share purchase warrants and $1,100,000 principal amount of 10% secured debentures due January 30, 2025 of SQI, representing approximately 21.17% of the issued and outstanding shares of SQI on a non-diluted basis and representing approximately 33.42% of the issued and outstanding shares of SQI, assuming the full exercise of all common share purchase warrants of SQI that Mr. Matthews beneficially owns or exercises control or direction over.

Immediately after the acquisition, Mr. Matthews beneficially owns or exercises control or direction over 70,271,165 common shares, 63,024,062 common share purchase warrants and $1,100,000 principal amount of 10% secured debentures due January 30, 2025 of SQI, representing approximately 25.39% of the issued and outstanding shares of SQI on a non-diluted basis and representing approximately 39.23% of the issued and outstanding shares of SQI, assuming the full exercise of all common share purchase warrants of SQI that Mr. Matthews beneficially owns or exercises control or direction over.

The securities described herein were acquired for investment purposes. Mr. Matthews may increase or decrease his investment, directly or indirectly, in securities of SQI from time to time, depending on market conditions or any other relevant factors.

A copy of the report relating to this acquisition may be found on SQI's profile at www.SEDAR.com or may be obtained from Mr. Matthews at 416-214-2226 or at Mr. Matthews' address: 200 King Street West, Suite 1702, Toronto, Ontario  M5H 3T4. SQI's head office is located at 36 Meteor Drive, Toronto, Ontario  M9W 1A4.

SOURCE Wilmot L. Matthews


These press releases may also interest you

at 09:15
n-Lorem, a nonprofit foundation, announced a new partnership with Hongene Biotech Corporation that supports n-Lorem's efforts to discover and provide personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1...

at 09:11
For over 30 years Protocall's behavioral health contact center, HelpNow, has set industry standards for round-the-clock access to high-quality crisis care. Received calls are documented within Protocall's custom database and sent to the caller's care...

at 09:10
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of a Phase II clinical study in minimal residual disease positive (MRD+) HPV-driven head and neck cancer. The study will be led by...

at 09:06
Memora Health, the leading intelligent care enablement platform, today announced an expansion of its leadership team with the addition of Divya Bhat as Chief Product Officer and Herman Ng as Chief Financial Officer. Divya and Herman bring unique...

at 09:05
Quantum Health, the leading consumer healthcare navigation and care coordination company, announced today the launch of its new end-to-end care management solution, Premier Oncology, tailored for employers and their members diagnosed with cancer....

at 09:05
United Therapeutics Corporation , a public benefit corporation, today announced the world's first successful transplant of a UThymoKidneytm, which the company produced, into a living person on April 12, 2024. This transplant represents several...



News published on and distributed by: